PMID- 19117034 OWN - NLM STAT- MEDLINE DCOM- 20090318 LR - 20211020 IS - 0008-543X (Print) IS - 1097-0142 (Electronic) IS - 0008-543X (Linking) VI - 115 IP - 2 DP - 2009 Jan 15 TI - Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. PG - 373-80 LID - 10.1002/cncr.23993 [doi] AB - BACKGROUND: An 11q22 deletion is considered an independent factor predicting poor survival in chronic lymphocytic leukemia (CLL). METHODS: We searched the electronic CLL database for consecutive patients who presented to the M. D. Anderson Cancer Center Department of Leukemia from October 2003 to April 2007 with untreated CLL and who had an 11q22 deletion, detected by fluorescence in situ hybridization (FISH) analysis of bone marrow samples. FISH analysis was performed using the following probes: trisomy 12 (12p11.1-q11), TP53 (17p13.1), ATM (11q22.3), LAMP1 (13q34), and D13S319 loci (13q14.3). RESULTS: Sixty-nine patients with untreated CLL with an 11q22 deletion were identified. The median patient age was 59 years (range, 26-81 years); 80% were men, 53% had Zubrod performance status>0, and 13% had Rai stage III to IV disease. Lymphadenopathy (massive), splenomegaly, anemia, and thrombocytopenia were present in 96% (12%), 19%, 9%, and 4%, respectively. In addition, 62% of patients had deletions in 13q, and 3% had trisomy 12. Forty patients required therapy for progressive disease. The overall response rates for FCR (fludarabine, cyclophosphamide, and rituximab), CFAR (FCR plus alemtuzumab), and rituximab plus granulocyte-macrophage colony-stimulating factor were 100%, 100%, and 33%, respectively. The 11q22 deletion was undetectable in 25 of 27 patients monitored after treatment using FISH analysis. The median follow-up was 17 months. At 1 and 3 years, the survival rates were 97% and 91%, respectively, and the relapse-free survival rates were 100% and 77%, respectively. CONCLUSIONS: CLL with an 11q22 deletion was associated with high rates of response, survival, and relapse-free survival when treated with chemoimmunotherapy. CI - Copyright (c) 2009 American Cancer Society. FAU - Tsimberidou, Apostolia-Maria AU - Tsimberidou AM AD - Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. atsimber@mdanderson.org FAU - Tam, Constantine AU - Tam C FAU - Abruzzo, Lynne V AU - Abruzzo LV FAU - O'Brien, Susan AU - O'Brien S FAU - Wierda, William G AU - Wierda WG FAU - Lerner, Susan AU - Lerner S FAU - Kantarjian, Hagop M AU - Kantarjian HM FAU - Keating, Michael J AU - Keating MJ LA - eng GR - P30 CA016672/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antibodies, Monoclonal, Murine-Derived) RN - 0 (Antibodies, Neoplasm) RN - 0 (Immunologic Factors) RN - 3A189DH42V (Alemtuzumab) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Alemtuzumab MH - Antibodies, Monoclonal/*administration & dosage MH - Antibodies, Monoclonal, Humanized MH - Antibodies, Monoclonal, Murine-Derived MH - Antibodies, Neoplasm/*administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Chromosome Deletion MH - Chromosomes, Human, Pair 11 MH - Female MH - Humans MH - Immunologic Factors/*administration & dosage MH - Leukemia, Lymphocytic, Chronic, B-Cell/genetics MH - Male MH - Middle Aged MH - Rituximab MH - Survival Rate PMC - PMC4404627 MID - NIHMS676510 EDAT- 2009/01/01 09:00 MHDA- 2009/03/19 09:00 PMCR- 2015/04/21 CRDT- 2009/01/01 09:00 PHST- 2009/01/01 09:00 [entrez] PHST- 2009/01/01 09:00 [pubmed] PHST- 2009/03/19 09:00 [medline] PHST- 2015/04/21 00:00 [pmc-release] AID - 10.1002/cncr.23993 [doi] PST - ppublish SO - Cancer. 2009 Jan 15;115(2):373-80. doi: 10.1002/cncr.23993.